Diazepam Binding Inhibitor (DBI) ELISA Kit for Human

Principle of the Assay: The microtiter plate provided in this kit has been pre-coated with an antibody specific to DBI. Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated antibody preparation specific to DBI. Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain DBI, biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of DBI in the samples is then determined by comparing the O.D. of the samples to the standard curve.

Intended Uses: The kit is a sandwich enzyme immunoassay for the in vitro quantitative measurement of DBI in human serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.

Small volumes of DBI elisa kit vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

MBS458785 is a ready-to-use microwell, strip-or-full plate ELISA (enzyme-linked immunosorbent assay) Kit for analyzing the presence of the Diazepam Binding Inhibitor (DBI) ELISA Kit target analytes in biological samples. The concentration gradients of the kit standards or positive controls render a theoretical kit detection range in biological research samples containing DBI. The ELISA analytical biochemical technique of the MBS458785 kit is based on DBI antibody-DBI antigen interactions (immunosorbency) and an HRP colorimetric detection system to detect DBI antigen targets in samples. The ELISA Kit is designed to detect native, not recombinant, DBI. Appropriate sample types may include undiluted body fluids and/or tissue homogenates, secretions. Quality control assays assessing reproducibility identified the intra-assay CV (%) and inter-assay CV(%).